SDMA: A sensitive early kidney filtration marker
SDMA blood testing measures symmetric dimethylarginine, a small amino acid derivative that appears when cells break down methyl-marked proteins. Inside the nucleus, enzymes add methyl groups to arginine residues on proteins (protein arginine methylation). When those proteins are recycled, the modified arginine is released as SDMA and enters the bloodstream. The body does not reuse SDMA for protein building; instead, it is carried in the blood and removed mainly by the kidneys, with little metabolic processing elsewhere.
Because the body produces SDMA at a fairly steady rate from normal cell turnover and the kidneys clear it efficiently, its blood level mirrors how well the kidneys are filtering small molecules (glomerular filtration). Unlike creatinine, SDMA depends less on muscle mass or diet, so it can offer a cleaner signal of filtration in many people. SDMA may also influence nitric oxide availability indirectly by affecting arginine transport, but its practical importance is as a sensitive readout of renal clearance. SDMA blood testing helps gauge kidney filtration performance.
Why SDMA picks up filtration loss before creatinine does
SDMA (symmetric dimethylarginine) is a small, protein‑derived molecule cleared almost entirely by the kidneys. Because its level rises as filtration falls—and is largely independent of muscle mass—it offers a whole‑body view of how efficiently blood is being cleansed of metabolic byproducts, with links to kidney, heart, and vascular health.
Big picture: SDMA complements creatinine, cystatin C, eGFR, urea nitrogen, electrolytes, and urine albumin to map renal and vascular physiology. Persistently higher values point to increased long‑term risks of chronic kidney disease progression and cardiovascular events, making SDMA a valuable early signal in protecting organ systems that depend on clean, well‑filtered blood.
Low, in-range, and high SDMA patterns
In most labs, SDMA has a tight reference interval; values clustering in the low‑to‑middle portion generally indicate robust glomerular filtration. Compared with creatinine, it changes earlier when kidney function slips, especially in people with low or variable muscle mass.
When SDMA runs lower than average, it typically reflects brisk filtration and efficient renal clearance. People usually feel well. It can be modestly lower in normal pregnancy because GFR rises, and it shows little systematic difference between men and women since it is not driven by muscle mass.
Higher SDMA signals reduced kidney filtration. As retention of solutes develops, people may notice fatigue, swelling, higher blood pressure, decreased exercise tolerance, or foamy urine. Chronically elevated levels track with anemia, mineral–bone changes, and higher cardiovascular risk. In older adults or those with low muscle mass, SDMA often uncovers kidney impairment that creatinine can miss.
Muscle mass, meals, and hydration effects on SDMA
Notes: Hydration, acute infection, recent high catabolic states, and drugs that transiently reduce GFR can shift SDMA. Pregnancy typically lowers it; older age trends it upward. Methods and reference intervals vary by lab. SDMA is distinct from ADMA (an NO synthase inhibitor); SDMA primarily indicates renal filtration.
Interpreting your SDMA number
SDMA (symmetric dimethylarginine) is a small protein-breakdown product released from cells and cleared almost entirely by the kidneys. Because its removal depends on glomerular filtration, an SDMA blood test tracks kidney filtering capacity (GFR) with minimal influence from muscle mass. Filtration underpins blood pressure control, electrolyte and acid–base balance, red cell production, toxin clearance, and therefore affects cardiovascular resilience, cognition, metabolism, and immunity.
Low values usually reflect efficient kidney filtration and dilution, or increased GFR states such as normal pregnancy. They can also reflect lower production of methylated arginine. Children and pregnant individuals often show lower SDMA due to physiologically higher filtration and are typically well.
Being in range suggests stable glomerular filtration and balanced protein turnover. Many clinicians view values in the low-to-mid portion of the reference interval as consistent with healthy renal reserve, given SDMA’s specificity for filtration.
High values usually reflect reduced kidney filtration (lower GFR) from acute illness or chronic kidney disease. SDMA may rise earlier than creatinine and is less biased by muscle mass, so elevations can flag early renal stress. Higher SDMA also tracks with cardiometabolic and inflammatory burden and tends to increase with age as GFR declines.
FAQs
SDMA (symmetric dimethylarginine) is a small amino acid derivative produced during normal protein turnover in the body. It is released into the bloodstream when methylated proteins are broken down and is cleared almost entirely by the kidneys through filtration. SDMA is important because its blood level directly reflects how well the kidneys are filtering waste (glomerular filtration rate, or GFR). Unlike creatinine, SDMA is minimally affected by muscle mass, making it a reliable marker for kidney function across different body types and ages. Monitoring SDMA helps detect early kidney stress, guide treatment decisions, and assess cardiovascular risk.
SDMA offers several advantages over creatinine for assessing kidney function. While creatinine levels can be influenced by muscle mass, age, sex, and diet, SDMA is minimally affected by these factors. This makes SDMA especially useful in individuals with low or high muscle mass, such as the elderly, children, or athletes. SDMA often rises earlier than creatinine in cases of kidney dysfunction, allowing for detection of reduced filtration. For the accurate assessment, SDMA is best interpreted alongside creatinine, cystatin C, urinalysis, and eGFR.
Elevated SDMA levels typically indicate reduced kidney filtration (lower GFR). Causes include chronic kidney disease, acute kidney injury, dehydration, urinary tract obstruction, and certain medications that impair renal function. High SDMA can also be seen in conditions associated with endothelial dysfunction, such as hypertension and diabetes. In pregnancy, elevated SDMA is concerning because filtration should naturally increase. Acute illness, inflammation, and drugs affecting kidney blood flow can also raise SDMA levels.
Symptoms associated with high SDMA and kidney stress include fatigue, swelling (edema), high blood pressure, nausea, itchy skin, and cognitive issues like “brain fog.” As kidney function declines, the body struggles to excrete waste and maintain fluid, mineral, and acid–base balance. Over time, complications such as anemia, bone–mineral disorders, and increased cardiovascular risk may develop. However, SDMA can rise before symptoms appear, making it a valuable early warning marker.
SDMA is measured through a blood test, with the accurate results obtained using LC-MS/MS (liquid chromatography–mass spectrometry). Normal SDMA values are typically low and fall within a narrow reference range, which may vary by age and pregnancy status. In healthy individuals, lower SDMA values indicate efficient kidney filtration. There is no universal “sweet spot” within the reference range, but values should be interpreted in the context of age, sex, and clinical status.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Oliva-Damaso, E., Oliva-Damaso, N., Rodriguez-Esparragon, F., Payan, J., Baamonde-Laborda, E., Gonzalez-Cabrera, F., Santana-Estupinan, R., & Rodriguez-Perez, J. C. (2019). Asymmetric (ADMA) and symmetric (SDMA) dimethylarginines in chronic kidney disease: a clinical approach. International Journal of Molecular Sciences, 20(15), 3668. https://doi.org/10.3390/ijms20153668
- National Institute of Diabetes and Digestive and Kidney Diseases. (2024). Chronic kidney disease tests & diagnosis. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/tests-diagnosis
- Kielstein, J. T., Salpeter, S. R., Bode-Boeger, S. M., Cooke, J. P., & Fliser, D. (2006). Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrology Dialysis Transplantation, 21(9), 2446-2451. https://doi.org/10.1093/ndt/gfl292
- Tutarel, O., Denecke, A., Bode-Böger, S. M., Martens-Lobenhoffer, J., Schieffer, B., Westhoff-Bleck, M., & Kielstein, J. T. (2011). Symmetrical dimethylarginine outperforms CKD-EPI and MDRD-derived eGFR for the assessment of renal function in patients with adult congenital heart disease. Kidney and Blood Pressure Research, 34(1), 41-45. https://doi.org/10.1159/000322614
- Pihlstrøm, H., Mjøen, G., Dahle, D. O., Pilz, S., Midtvedt, K., März, W., Abedini, S., Holme, I., Fellström, B., Jardine, A., & Holdaas, H. (2014). Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipients. Transplantation, 98(11), 1219-1225. https://doi.org/10.1097/TP.0000000000000205






































.avif)

